These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 18489760)

  • 1. Access to high cost medicines in Australia: ethical perspectives.
    Lu CY; Macneill P; Williams K; Day R
    Aust New Zealand Health Policy; 2008 May; 5():4. PubMed ID: 18489760
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The views of stakeholders on controlled access schemes for high-cost antirheumatic biological medicines in Australia.
    Lu CY; Ritchie J; Williams K; Day R
    Aust New Zealand Health Policy; 2007 Dec; 4():26. PubMed ID: 18096055
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Has the use of disease-modifying anti-rheumatic drugs changed as a consequence of controlled access to high-cost biological agents through the Pharmaceutical Benefits Scheme?
    Lu CY; Williams KM; Day RO
    Intern Med J; 2007 Sep; 37(9):601-6. PubMed ID: 17542999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent developments in targeting access to high cost medicines in Australia.
    Lu CY; Ritchie J; Williams KM; Day RO
    Aust New Zealand Health Policy; 2005 Nov; 2():28. PubMed ID: 16305742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence-based decision-making within Australia's pharmaceutical benefits scheme.
    Lopert R
    Issue Brief (Commonw Fund); 2009 Jul; 60():1-13. PubMed ID: 19639714
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transparency in pricing arrangements for medicines listed on the Australian Pharmaceutical Benefits Scheme.
    Robertson J; Walkom EJ; Henry DA
    Aust Health Rev; 2009 May; 33(2):192-9. PubMed ID: 19563308
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The funding and use of high-cost medicines in Australia: the example of anti-rheumatic biological medicines.
    Lu CY; Williams KM; Day RO
    Aust New Zealand Health Policy; 2007 Mar; 4():2. PubMed ID: 17331230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Studies using Australia's Pharmaceutical Benefits Scheme data for pharmacoepidemiological research: a systematic review of the published literature (1987-2013).
    Pearson SA; Pesa N; Langton JM; Drew A; Faedo M; Robertson J
    Pharmacoepidemiol Drug Saf; 2015 May; 24(5):447-55. PubMed ID: 25833702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The UNESCO Bioethics Declaration 'social responsibility' principle and cost-effectiveness price evaluations for essential medicines.
    Faunce TA
    Monash Bioeth Rev; 2005 Jul; 24(3):10-9. PubMed ID: 16302317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Pharmaceutical Benefits Scheme and implications for paediatric prescribing.
    Sinha Y; Brien JA; Craig JC
    J Paediatr Child Health; 2009 Jun; 45(6):351-7. PubMed ID: 19490409
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The influence of the Pharmaceutical Benefits Scheme (PBS) on inappropriate prescribing in Australian nursing homes.
    King MA; Roberts MS
    Pharm World Sci; 2007 Feb; 29(1):39-42. PubMed ID: 17268937
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost driver analysis of statin expenditure on Australia's Pharmaceutical Benefits Scheme.
    Thai LP; Moss JR; Godman B; Vitry AI
    Expert Rev Pharmacoecon Outcomes Res; 2016 Jun; 16(3):419-33. PubMed ID: 26707482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Personal Importation and the Law: Protecting Patients Who Import Medicines for Legitimate Health Care Needs.
    Ghinea N
    J Law Med; 2022 Aug; 29(3):829-846. PubMed ID: 36056668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distributional impact of higher patient contributions to Australia's Pharmaceutical Benefits Scheme.
    Walker A
    Aust Health Rev; 2000; 23(2):32-46. PubMed ID: 11010578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Policy challenges of nanomedicine for Australia's PBS.
    Faunce TA
    Aust Health Rev; 2009 May; 33(2):258-67. PubMed ID: 19563314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Australian pharmaceutical policy: price control, equity, and drug innovation in Australia.
    Doran E; Alexander Henry D
    J Public Health Policy; 2008 Apr; 29(1):106-20. PubMed ID: 18368023
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Funding antiretroviral treatment for HIV-positive temporary residents in Australia prevents transmission and is inexpensive.
    Gray RT; Watson J; Cogle AJ; Smith DE; Hoy JF; Bastian LA; Finlayson R; Drummond FM; Whittaker B; Law MG; Petoumenos K
    Sex Health; 2018 Feb; 15(1):13-19. PubMed ID: 28874236
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A perspective on Australia's National Medicines Policy.
    Tett SE
    Can J Clin Pharmacol; 2004; 11(1):e28-38. PubMed ID: 15226524
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retrospective comparison of Australia's Pharmaceutical Benefits Scheme claims data with prescription data in HER2-positive early breast cancer patients, 2008-2012.
    Harris C; Daniels B; Ward RL; Pearson SA
    Public Health Res Pract; 2017 Dec; 27(5):. PubMed ID: 31044212
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.